EPISODE · Feb 17, 2016 · 3 MIN
Third Generation EGFR TKIs for Acquired Resistance
from GRACEcast · host cancerGRACE Meetings
Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.
What this episode covers
Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.
NOW PLAYING
Third Generation EGFR TKIs for Acquired Resistance
No transcript for this episode yet
Similar Episodes
Jul 2, 2026 ·56m
Jul 1, 2026 ·43m
Jun 28, 2026 ·8m
Jun 25, 2026 ·61m
Jun 24, 2026 ·51m
Jun 21, 2026 ·15m